Adrenergic Uptake Inhibitors
"Adrenergic Uptake Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
| Descriptor ID |
D018759
|
| MeSH Number(s) |
D27.505.519.562.437.050 D27.505.519.625.050.601 D27.505.519.625.600.050 D27.505.696.577.050.601 D27.505.696.577.600.050
|
| Concept/Terms |
Adrenergic Uptake Inhibitors- Adrenergic Uptake Inhibitors
- Inhibitors, Adrenergic Reuptake
- Reuptake Inhibitors, Adrenergic
- Uptake Inhibitors, Adrenergic
- Adrenergic Reuptake Inhibitors
- Inhibitors, Adrenergic Uptake
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic Uptake Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic Uptake Inhibitors".
This graph shows the total number of publications written about "Adrenergic Uptake Inhibitors" by people in this website by year, and whether "Adrenergic Uptake Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic Uptake Inhibitors" by people in Profiles.
-
McBurnett K, Clemow D, Williams D, Villodas M, Wietecha L, Barkley R. Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms. J Child Adolesc Psychopharmacol. 2017 02; 27(1):38-42.
-
Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses. 2011 Apr; 5(1):17-25.
-
Waxmonsky JG, Waschbusch DA, Akinnusi O, Pelham WE. A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011 Feb; 21(1):21-32.
-
Tamayo JM, Pumariega A, Rothe EM, Kelsey D, Allen AJ, V?lez-Borr?s J, Williams D, Anderson SG, Durell TM. Latino versus Caucasian response to atomoxetine in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008 Feb; 18(1):44-53.
-
Piletz JE, Halaris AE, Chikkala D, Qu Y. Platelet I1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients. J Psychiatr Res. 1996 May-Jun; 30(3):169-84.